Look Under The Hood: IVOV Has 18% Upside
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 29 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The Vanguard S&P Mid-Cap 400 Value ETF (IVOV) has an implied analyst target price of $108.40, indicating a potential upside of 17.72% from its current trading price of $92.08 per unit.
Individual Holdings Upside Potential: Notable underlying holdings such as Novanta Inc, UFP Industries Inc, and Rayonier Inc show significant upside potential, with analysts projecting increases of 33.53%, 23.19%, and 23.13% respectively, compared to their recent share prices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NOVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NOVT
About NOVT
Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novanta Inc. CFO to Present at Jefferies Global Healthcare Conference
- Executive Presentation Scheduled: Novanta Inc.'s CFO Robert Buckley is set to present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York, highlighting the company's leadership in medical technology and likely attracting investor interest.
- Company Overview: Novanta is a leading global supplier of core technology solutions, focusing on providing competitive advantages to medical and advanced industrial equipment manufacturers, leveraging deep expertise in precision medicine, manufacturing, medical solutions, and robotics.
- Technological Edge: The company engineers core components and sub-systems that deliver extreme precision and performance, addressing complex technical challenges to meet demanding customer applications, thereby driving business growth.
- Innovation-Driven Team: The growth of Novanta is fueled by a team of professionals committed to innovation and customer success, reflecting the company's ongoing investment in technology and its strong focus on meeting customer needs.
See More
Novanta Reports Strong Q1 2026 Earnings with 37% Bookings Growth
- Significant Performance Growth: Novanta achieved a 10% reported growth and 3% organic growth in Q1 2026, exceeding market expectations and demonstrating strong performance in demand and bookings acceleration.
- Optimistic Order and Revenue Outlook: The company reported a 37% year-over-year increase in bookings with a book-to-bill ratio of 1.10, and it expects organic growth to reach high single digits in Q2, indicating sustained revenue growth ahead.
- New Product Revenue Surge: New product revenue rose by 50% year-over-year, with accelerating growth in AI infrastructure-related applications, which is expected to provide broader market opportunities, particularly amid a recovery in the semiconductor market.
- Strong Financial Position: The company reported a non-GAAP adjusted gross profit of $118 million with a gross margin of 45.6%, alongside a significant improvement in cash flow, achieving operating cash flow of $52 million, showcasing flexibility in addressing cost pressures and investments.
See More
Novanta Inc Reports 10% Revenue Growth in Q1 2026
- Significant Revenue Growth: Novanta Inc reported a 10% revenue increase in Q1, with 3% organic growth, surpassing market expectations and demonstrating strong performance in the industry.
- Strong Order Book: The company experienced a 37% year-over-year increase in bookings, with a book-to-bill ratio of 1.10, indicating robust market demand and potential for sustained revenue growth.
- Solid Profit Performance: Adjusted EBITDA grew by 14% and adjusted diluted EPS increased by 9%, reflecting the company's strong profitability despite a slight decline in gross margins due to rising costs.
- AI Market Potential: The company is gaining momentum in AI-driven robotics, automation, and minimally invasive surgery markets, with new product revenue up 50% year-over-year, showcasing its competitive edge in rapidly evolving technology sectors.
See More
Novanta to Release Q1 2026 Results and Host Conference Call
- Earnings Release Schedule: Novanta Inc. will release its Q1 2026 financial results after the U.S. market closes on May 11, 2026, reflecting the company's ongoing performance in the medical and advanced technology equipment sectors.
- Conference Call Timing: The company will host a conference call on May 12, 2026, at 8:00 a.m. ET to discuss the earnings report, which is expected to attract significant attention from investors and analysts.
- Access Methods: Investors can join the call by dialing (888) 346-3959 or accessing the live webcast on the company's Events & Presentations page, ensuring timely information dissemination.
- Replay Availability: An audio replay will be available approximately three hours after the call concludes and will remain accessible until July 6, 2026, allowing investors who missed the live event to catch up on the discussion.
See More
Novanta Joins NVIDIA Halos AI Systems Inspection Lab to Enhance Robotics Safety
- Collaboration Accelerates Certification: Novanta Inc. announced its participation in the NVIDIA Halos AI Systems Inspection Lab, the first ANSI National Accreditation Board (ANAB) accredited lab for AI-driven physical systems, aimed at accelerating certification processes and enhancing trust in key components, thereby driving the next generation of robotics and physical AI systems.
- Interoperability Validation: Through collaboration with NVIDIA, Novanta will validate the interoperability of its motion control and sensing technologies with safety requirements of NVIDIA platforms, including NVIDIA IGX Thor, which will simplify OEMs' integration complexities and accelerate time-to-market.
- Advancing Safety Standards: The Halos AI Systems Inspection Lab supports ecosystem participants in validating and certifying technologies for AI-powered systems, and Novanta's involvement will assist robotics developers in building advanced warehouse automation and industrial robotics platforms, promoting the adoption of robotic safety standards.
- Market Competitive Advantage: Novanta is committed to providing core technology solutions for medical and advanced industrial OEMs, and its collaboration with NVIDIA reinforces its market position in accelerating physical AI applications, ensuring its technologies are widely adopted across logistics, manufacturing, and other sectors.
See More
Harvey Partners Acquires New Position in Novanta
- New Investment Disclosure: On February 17, 2026, Harvey Partners disclosed a new position by acquiring 304,000 shares of Novanta worth $36.17 million, indicating confidence in the company's future prospects.
- Asset Allocation Analysis: This acquisition accounts for 3.21% of Harvey Partners' 13F reportable assets, highlighting Novanta's significance within the fund's investment portfolio.
- Company Financial Status: As of February 17, 2026, Novanta's stock price stood at $145.37, remaining flat over the past year and underperforming the S&P 500's 16% gain, raising concerns about its profitability.
- Future Outlook: Despite a 3% year-over-year revenue increase to $980.6 million in 2025, net income fell from $64.1 million to $53.8 million, with the CEO stating plans to improve margins and cash flow, making it crucial for investors to monitor these developments.
See More
Novanta Inc. CFO to Present at Jefferies Global Healthcare Conference
- Executive Presentation Scheduled: Novanta Inc.'s CFO Robert Buckley is set to present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York, highlighting the company's leadership in medical technology and likely attracting investor interest.
- Company Overview: Novanta is a leading global supplier of core technology solutions, focusing on providing competitive advantages to medical and advanced industrial equipment manufacturers, leveraging deep expertise in precision medicine, manufacturing, medical solutions, and robotics.
- Technological Edge: The company engineers core components and sub-systems that deliver extreme precision and performance, addressing complex technical challenges to meet demanding customer applications, thereby driving business growth.
- Innovation-Driven Team: The growth of Novanta is fueled by a team of professionals committed to innovation and customer success, reflecting the company's ongoing investment in technology and its strong focus on meeting customer needs.
See More
Novanta Reports Strong Q1 2026 Earnings with 37% Bookings Growth
- Significant Performance Growth: Novanta achieved a 10% reported growth and 3% organic growth in Q1 2026, exceeding market expectations and demonstrating strong performance in demand and bookings acceleration.
- Optimistic Order and Revenue Outlook: The company reported a 37% year-over-year increase in bookings with a book-to-bill ratio of 1.10, and it expects organic growth to reach high single digits in Q2, indicating sustained revenue growth ahead.
- New Product Revenue Surge: New product revenue rose by 50% year-over-year, with accelerating growth in AI infrastructure-related applications, which is expected to provide broader market opportunities, particularly amid a recovery in the semiconductor market.
- Strong Financial Position: The company reported a non-GAAP adjusted gross profit of $118 million with a gross margin of 45.6%, alongside a significant improvement in cash flow, achieving operating cash flow of $52 million, showcasing flexibility in addressing cost pressures and investments.
See More
Novanta Inc Reports 10% Revenue Growth in Q1 2026
- Significant Revenue Growth: Novanta Inc reported a 10% revenue increase in Q1, with 3% organic growth, surpassing market expectations and demonstrating strong performance in the industry.
- Strong Order Book: The company experienced a 37% year-over-year increase in bookings, with a book-to-bill ratio of 1.10, indicating robust market demand and potential for sustained revenue growth.
- Solid Profit Performance: Adjusted EBITDA grew by 14% and adjusted diluted EPS increased by 9%, reflecting the company's strong profitability despite a slight decline in gross margins due to rising costs.
- AI Market Potential: The company is gaining momentum in AI-driven robotics, automation, and minimally invasive surgery markets, with new product revenue up 50% year-over-year, showcasing its competitive edge in rapidly evolving technology sectors.
See More
Novanta to Release Q1 2026 Results and Host Conference Call
- Earnings Release Schedule: Novanta Inc. will release its Q1 2026 financial results after the U.S. market closes on May 11, 2026, reflecting the company's ongoing performance in the medical and advanced technology equipment sectors.
- Conference Call Timing: The company will host a conference call on May 12, 2026, at 8:00 a.m. ET to discuss the earnings report, which is expected to attract significant attention from investors and analysts.
- Access Methods: Investors can join the call by dialing (888) 346-3959 or accessing the live webcast on the company's Events & Presentations page, ensuring timely information dissemination.
- Replay Availability: An audio replay will be available approximately three hours after the call concludes and will remain accessible until July 6, 2026, allowing investors who missed the live event to catch up on the discussion.
See More
Novanta Joins NVIDIA Halos AI Systems Inspection Lab to Enhance Robotics Safety
- Collaboration Accelerates Certification: Novanta Inc. announced its participation in the NVIDIA Halos AI Systems Inspection Lab, the first ANSI National Accreditation Board (ANAB) accredited lab for AI-driven physical systems, aimed at accelerating certification processes and enhancing trust in key components, thereby driving the next generation of robotics and physical AI systems.
- Interoperability Validation: Through collaboration with NVIDIA, Novanta will validate the interoperability of its motion control and sensing technologies with safety requirements of NVIDIA platforms, including NVIDIA IGX Thor, which will simplify OEMs' integration complexities and accelerate time-to-market.
- Advancing Safety Standards: The Halos AI Systems Inspection Lab supports ecosystem participants in validating and certifying technologies for AI-powered systems, and Novanta's involvement will assist robotics developers in building advanced warehouse automation and industrial robotics platforms, promoting the adoption of robotic safety standards.
- Market Competitive Advantage: Novanta is committed to providing core technology solutions for medical and advanced industrial OEMs, and its collaboration with NVIDIA reinforces its market position in accelerating physical AI applications, ensuring its technologies are widely adopted across logistics, manufacturing, and other sectors.
See More
Harvey Partners Acquires New Position in Novanta
- New Investment Disclosure: On February 17, 2026, Harvey Partners disclosed a new position by acquiring 304,000 shares of Novanta worth $36.17 million, indicating confidence in the company's future prospects.
- Asset Allocation Analysis: This acquisition accounts for 3.21% of Harvey Partners' 13F reportable assets, highlighting Novanta's significance within the fund's investment portfolio.
- Company Financial Status: As of February 17, 2026, Novanta's stock price stood at $145.37, remaining flat over the past year and underperforming the S&P 500's 16% gain, raising concerns about its profitability.
- Future Outlook: Despite a 3% year-over-year revenue increase to $980.6 million in 2025, net income fell from $64.1 million to $53.8 million, with the CEO stating plans to improve margins and cash flow, making it crucial for investors to monitor these developments.
See More
